Today's Rundown Seattle Genetics' breast cancer drug hits mark in pivotal trial Ex-Obama health official becomes Google's first chief health officer After $700M-plus Merck buyout, Tilos CEO Fox lands at Rheos Medicines [Sponsored] Advancing Site-Sponsor Relationships Verseau bags $50M for cancer R&D, names Golumbeski as chairman Aerpio may hang the 'for sale' sign up, axes CEO after eye drug flop The top AI lighthouse projects to watch in biopharma Featured Story | | | Monday, October 21, 2019 A pivotal trial of Seattle Genetics’ tucatinib in patients with HER2-positive breast cancer has met its primary endpoint. The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year. |
|
|---|
|
Top Stories Friday, October 18, 2019 Google snagged Karen DeSalvo, a former health official in the Obama administration, to become its first chief health officer. Her appointment is just the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare, including those of former FDA Commissioner Robert Califf and ex-Geisinger CEO David Feinberg. Monday, October 21, 2019 Barbara Fox, Ph.D., is getting right back on the horse. Fresh off Tilos Therapeutics’ $773 million sale to Merck, Fox is taking the helm of another Cambridge, Massachusetts-based company: Rheos Medicines. Monday, October 21, 2019 Clinical trials involve massive complexity and, often, systems that lack consistency and discipline. With a new perspective to an old problem, WCG coordinates the execution of six proven strategies to dramatically and consistently bring clinical studies to launch faster and at a lower cost. Monday, October 21, 2019 Verseau Therapeutics has raised $50 million to develop macrophage-targeted immunotherapies. The startup, which appointed George Golumbeski as chairman, will use the money to take macrophage checkpoint modulators into the clinic. Monday, October 21, 2019 In a classic plot line for biotechs, Aerpio is seeking a “strategic review” for its business and assets after being hit by a trial failure for its leading med earlier this year. Monday, October 21, 2019 As the biopharma industry’s digital transformation continues apace, with the rapid acceptance of tools such as artificial intelligence and machine learning, certain projects promise to yield impacts on a much wider scale. | | Better than the other transgenics.
Better than in vitro display.
Better than humanization. AlivaMabTM Mouse from Ablexis delivers quality, speed and value in generating development-ready antibodies that meet your target product profile. Contact us at info@ablexis.com to learn more. ablexis.com |
Resources Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 